EGFR and prostate cancer: Figure 5A demonstrates that the most enriched pathways are primarily associated with oncogenic and endocrine signaling, encompassing the prolactin signaling pathway, PI3K-Akt signaling pathway, resistance to EGFR tyrosine kinase inhibitors, central carbon metabolism in cancer, non-small cell lung cancer, prostate cancer, endocrine resistance, neurotrophin signaling pathway, and breast cancer.